The pathway to secondary prevention of Alzheimer's disease
| Autor: | David Miller, H. Robert Brashear, Christopher J. Weber, Christopher Randolph, Eric McDade, Paul Maruff, Lisa J. Bain, Martin M. Bednar, Zahinoor Ismail, Maria C. Carrillo, Ann Marie Hake |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Gerontology Disease 03 medical and health sciences 0302 clinical medicine research roundtable Medicine RC346-429 Secondary prevention clinical trials business.industry RC952-954.6 biomarkers Alzheimer's disease Clinical trial Psychiatry and Mental health 030104 developmental biology Drug development Geriatrics Perspective Neurology. Diseases of the nervous system Neurology (clinical) business Preclinical stage 030217 neurology & neurosurgery Perspectives |
| Zdroj: | Alzheimer's & Dementia : Translational Research & Clinical Interventions Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020) |
| ISSN: | 2352-8737 |
| Popis: | Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre‐clinical AD. This review will address the biological approach to defining pre‐clinical AD, detection, identification of at‐risk individuals, and lessons learned from trials such as A4 and TOMMORROW. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text